Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft Model

Autor: Timothy M. Crombleholme, Shyra J. Miller, Yonatan Y. Mahller, Maria Ripberger, Nancy Ratner, Margaret H. Collins, Sachin S. Vaikunth, Timothy P. Cripe, Mark A. Currier, Ruty Mehrian-Shai, Ya-Hsuan Hsu
Rok vydání: 2007
Předmět:
Angiogenesis
Mice
SCID

Nerve Sheath Neoplasms
Mice
0302 clinical medicine
Mice
Inbred NOD

Chlorocebus aethiops
Drug Discovery
Simplexvirus
Epidermal growth factor receptor
Cells
Cultured

In Situ Hybridization
Oligonucleotide Array Sequence Analysis
EGFR inhibitors
Oncolytic Virotherapy
0303 health sciences
Neovascularization
Pathologic

biology
Reverse Transcriptase Polymerase Chain Reaction
3. Good health
ErbB Receptors
030220 oncology & carcinogenesis
Molecular Medicine
Rabbits
Erlotinib
medicine.drug
Immunoblotting
Malignant peripheral nerve sheath tumor
Virus
Cell Line
Erlotinib Hydrochloride
03 medical and health sciences
Cell Line
Tumor

Genetics
medicine
Animals
Humans
Protein Kinase Inhibitors
Vero Cells
Molecular Biology
030304 developmental biology
Pharmacology
business.industry
Genetic Therapy
medicine.disease
Xenograft Model Antitumor Assays
Oncolytic virus
Viral replication
Immunology
Quinazolines
Cancer research
biology.protein
business
Zdroj: Molecular Therapy. 15:279-286
ISSN: 1525-0016
DOI: 10.1038/sj.mt.6300038
Popis: Malignant peripheral nerve sheath tumors (MPNSTs), driven in part by hyperactive Ras and epidermal growth factor receptor (EGFR) signaling, are often incurable. Testing of therapeutics for MPNST has been hampered by lack of adequate xenograft models. We previously documented that human MPNST cells are permissive for lytic infection by oncolytic herpes simplex viruses (oHSV). Herein we developed and characterized a xenograft model of human MPNST and evaluated the antitumor effects of oHSV mutants (G207 and hrR3) and the EGFR inhibitor, erlotinib. Additive cytotoxicity of these agents was found in human MPNST cell lines, suggesting that EGFR signaling is not critical for virus replication. Mice bearing human MPNST tumors treated with G207 or hrR3 by intraperitoneal or intratumoral injection showed tumor-selective virus biodistribution, virus replication, and reduced tumor burden. oHSV injection demonstrated more dramatic antitumor activity than erlotinib. Combination therapies showed a trend toward an increased antiproliferative effect. Both oHSV and erlotinib were antiangiogenic as measured by proangiogenic gene expression, effect on endothelial cells and xenograft vessel density. Overall, oHSVs showed highly potent antitumor effects against MPNST xenografts, an effect not diminished by EGFR inhibition. Our data suggest that inclusion of MPNSTs in clinical trials of oHSV is warranted.
Databáze: OpenAIRE